TickerTalks
Browse all tickers →
TickerTalks›$IMVT
IMIMVT

Immunovant, Inc.

$IMVT·$8.2B·Biotechnology·Healthcare
$38.96-2.3%YTD+52.3%1Y+118.8%
Mentions · last 7 days
2026-07-09: 5 posts2026-07-10: 3 posts2026-07-11: 0 posts2026-07-12: 0 posts2026-07-13: 4 posts2026-07-14: 1 posts2026-07-15: 2 posts15-32%
Price updated 5h ago·X counts updated 1d ago
IMIMVT
$IMVTImmunovant, Inc.
$38.96-2.31%15 posts-32%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $IMVT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-07-16

The move is getting stronger, with heavier trading behind it.

FcRn autoimmune-platform biotech running into a dense readout cadence with the parent's phones ringing from pharma.

Immunovant develops anti-FcRn antibodies for autoimmune disease — IMVT-1402 is the potentially best-in-class successor to lead asset batoclimab, aimed at rheumatoid arthritis and myasthenia gravis with a subcutaneous-dosing profile designed to compete with argenx's Vyvgart.

  • Shares are up 128% over twelve months and 56% year-to-date, sitting at the 95th percentile of the 52-week range with volume at only 49% of the 30-day average — a well-held tape rather than a chase.
  • The rheumatoid arthritis Phase 2b readout in May validated the platform, prompting analyst upgrades; 11 analysts model a $2.61 loss for fiscal-26 on very early revenue as pipeline value dominates.
  • Insider activity is one-directional: fifteen sale events show up in the pack, all at roughly $39.55 across ten-percent-holder Roivant-affiliated names — administrative rather than a break in conviction.
  • Balance sheet reads clean: debt-to-equity is effectively zero, ROIC is negative because R&D dominates the P&L, and the operating-margin denominator is not meaningful.

The next earnings release is 10 August; the more relevant catalysts are readout timing on the RA programme and the pattern of business-development conversations Roivant's CEO has referenced publicly — the setup is a platform biotech where the fundamental picture will keep being about milestones rather than P&L.

Agrees with X sentimentX frames it as a $40 launch pad citing prior mid-cap biotech setups that ran multiples of that, with the Roivant CEO noting inbound calls from pharma. That matches the analyst-upgrade cadence and the RA-Phase-2b validation — the crowd is more explicit than the model on how much the tape has already priced.

What to watch: The 10 August fiscal-Q1 print — pipeline update on IMVT-1402 in RA and Graves', Phase 3 readout timing, and cash-runway commentary. Any Roivant-affiliated 13D/A signalling changed position stance would also matter.

On the calendar: Q1 earnings 10 August 2026 (Phase 3 readouts ongoing)

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-03

Immunovant (IMVT) is being discussed with $ROIV CEO Gline noting phone calls from Pharma about IMVT all the time. Community frames IMVT at $40 as launch pad like prior 40->340 setups. The tone is aggressive long positioning into the biotech catalyst.

Read the AI verdict + X sentiment for $IMVT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops FcRn antibody inhibitors that reduce pathogenic IgG antibodies for treating autoimmune and inflammatory diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IMVT.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $IMVT

Partial — Develops FcRn antibody inhibitors that reduce pathogenic IgG antibodies for treating autoimmune and inflammatory diseases; this segment overlaps with the GLP-1 pipeline bifurcation and ADA oral formulation competition but is not the dominant revenue driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-12.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-62.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-68.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 20, 2026$-0.73$-0.59-23.3%
Q4 2025Feb 6, 2026$-0.61$-0.72+15.3%
Q3 2025Nov 10, 2025$-0.73$-0.72-1.4%
Q2 2025Aug 11, 2025$-0.60$-0.69+13.0%
Next earningsMon, Aug 10·consensus EPS $-0.66

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY26$0———$-0.73$-95.1M
Q3 FY26$0———$-0.61$-92.3M
Q2 FY26$0———$-0.73$-102.5M
Q1 FY26$0———$-0.71$-117.4M

Forward consensus

6-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$10.5M$10.5M – $10.5M-$2.61-$2.85 – -$2.488
FY27$6.6M$6.6M – $6.6M-$2.65-$3.03 – -$2.469
FY28$52.3M$52.3M – $52.3M-$2.66-$2.91 – -$2.429
FY29$507.7M$507.7M – $507.7M-$1.42-$2.86 – -$0.0210
FY30$991.2M$991.2M – $991.2M$0.37$0.37 – $0.375
FY31$1.6B$1.6B – $1.6B$2.30$2.30 – $2.304

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.92%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+14.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+45.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 78.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.775-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 8Melanie GloriaCOO2.0K sh$81KSellJul 8Van Tuyl ChristopherChief Legal Officer1.2K sh$48KSellJul 8Jay S StoutCTO3.5K sh$138KSellJul 2Eric VenkerCEO3.1K sh$119KSellJun 26Atul PandeDirector1.5K sh$57KSellJun 26Melanie GloriaCOO17.7K sh$679KSellJun 26Jay S StoutCTO40.0K sh$1.5MSellJun 26Tiago GiraoCFO10.0K sh$385KSellJun 26Van Tuyl ChristopherChief Legal Officer17.8K sh$683KSellJun 18Van Tuyl ChristopherChief Legal Officer2.6K sh$93K
1–10 of 24
+ 21 other (11 awards · 8 exempts · 2 returns) in window

See when $IMVT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 4 other (2 earnings 8-Ks · 1 10-K · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?zacks.com·28d agoImmunovant Stock Gains 12.4% in a Month: What's Driving It?zacks.com·35d agoImmunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potentialseekingalpha.com·53d agoRoivant: Immunovant's Rheumatoid Arthritis Win Validates The Buyseekingalpha.com·57d agoThese Analysts Increase Their Forecasts On Immunovant After Q4 Resultsbenzinga.com·57d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · last 7 days

No standout posts about $IMVT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport